Abstract #0018

Improvement of 2-hydroxyglutarate detectability using optimized triple-refocusing difference editing at 7T in vivo

Sandeep K Ganji¹, Zhongxu An¹, Vivek Tiwari¹, Marco Pinho², Edward Pan³, Bruce Mickey⁴, Elizabeth Maher⁵, and Changho Choi¹

¹Advanced Imaging Research Center, UT Southwestern Medical Center, Dallas, TX, United States, ²Radiology, UT Southwestern Medical Center, Dallas, TX, United States, ³Neurology and Neurotherapeutic, UT Southwestern Medical Center, Dallas, TX, United States, ⁴Neurological Surgery, UT Southwestern Medical Center, Dallas, TX, United States, ⁵Internal Medicine, UT Southwestern Medical Center, Dallas, TX, United States

2-hydroxyglutarate (2HG) has become an important biomarker in the diagnosis and management of glioma patients as well as in the workup of an undiagnosed mass. The 1H MRS signals of 2HG are extensively overlapped with other metabolite signals. Specifically, uncertainty in 2HG evaluation arising from the spectral overlap of the 2HG 2.25-ppm signal with the GABA 2.29-ppm resonance may be a major obstacle when the 2HG level is relatively low. Here we report a novel triple-refocusing difference editing that provides complete differentiation between 2HG and GABA signals at 7T.

This abstract and the presentation materials are available to members only; a login is required.

Join Here